AstraZeneca Signs an Exclusive Promotion Agreement with Luye Pharma for its Xuezhikang in China
Shots:
- AstraZeneca to get exclusive promotion rights in China including Taiwan, Hong Kong, Singapore, Malaysia for Luye’s Xuezhikang capsules. Luye Pharma will retain its IPR, commercialization rights, asset rights & registration permit rights
- The focus of the agreement is to promote Xuezhikang in cardiovascular disorders and strengthening Luye’s footprints in cardiology, with its further expansion in the US and EU
- Xuezhikang is a lipid-regulating candidate used for maintaining abnormal blood lipids and is evaluated in P-II trial for patients with LDL-C
Click here to read full press release/ article | Ref: Luye Pharma | Image: LinkedIn